August 4, 2026 — Leads & Copy — Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2026, reporting total revenues of $308 million, a 17% increase year-over-year on an adjusted basis. The company highlighted strong commercial performance from its key products, DAYBUE and NUPLAZID.
Catherine Owen Adams, Chief Executive Officer of Acadia, stated that continued patient demand and robust uptake of STIX contributed to DAYBUE’s strong performance. NUPLAZID also demonstrated momentum, particularly in new-to-brand prescriptions, benefiting from the recently expanded sales force. Both franchises are projected to achieve approximately $1.7 billion in annual net sales by 2028.
Acadia is anticipating topline results from its Phase 2 program evaluating remlifanserin for Alzheimer’s disease psychosis between September and October 2026, a development the company views as a potentially transformational opportunity.
Significant company updates include the completion of enrollment in the Phase 2 portion of the RADIANT program for remlifanserin and the initiation of Phase 3 screening and enrollment. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis, acknowledging its potential to address a significant unmet medical need.
In Europe, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would be the first authorized treatment for Rett syndrome in the European Union.
For the second quarter of 2026, GAAP total revenues were $308 million, an increase of 16% compared to $265 million in the second quarter of 2025. GAAP net product sales of NUPLAZID reached $183 million, up 9% from $168 million in the prior year’s second quarter. Net product sales for DAYBUE were $125 million, representing a 30% increase from $96 million in the second quarter of 2025.
Research and development expenses for the second quarter of 2026 were $82 million, compared to $78 million for the same period in 2025. Selling, general, and administrative expenses increased to $160 million from $134 million in the prior year’s second quarter.
Acadia reported a net income of $32 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net income of $27 million, or $0.16 per diluted share, for the same period in 2025. The company’s cash, cash equivalents, and investment securities totaled $956 million as of June 30, 2026, an increase from $820 million at December 31, 2025.
Acadia has updated its full-year 2026 financial guidance. Total revenues are now projected to be in the range of $1.24 billion to $1.30 billion. NUPLAZID net product sales are expected to be between $760 million and $790 million. Global net product sales for DAYBUE are forecasted at $480 million to $510 million. R&D expenses are projected to be between $355 million and $380 million, with SG&A expenses estimated between $660 million and $700 million.
Acadia Pharmaceuticals Inc. is dedicated to transforming scientific promise into meaningful innovation for underserved neurological and rare disease communities. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.
Source: Acadia Pharmaceuticals Inc.
